New-onset vitiligo following proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab: A possible immune-mediated adverse effect.

Carlos A Umaña Mejia, Mariana Olvera Morales, Alan Jurado Orozco, Jose D Burgos

Abstract readCase Reports

In one paragraph

Article in JAAD case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carlos A Umaña MejiaUniversidad Autónoma de Guadalajara, Facultad de Medicina, Guadalajara, Jalisco, Mexico.

Mariana Olvera MoralesUniversidad Autónoma de Guadalajara, Facultad de Medicina, Guadalajara, Jalisco, Mexico.

Alan Jurado OrozcoInternal Medicine Resident, University Medical Center of El Paso, Texas Tech University Health Sciences Center, El Paso, Texas.

Jose D BurgosHospitalist Department, Director, University Medical Center of El Paso, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biologic therapydrug-induced vitiligoevolocumabhyperlipidemiaimmune-mediated adverse eventPCSK9 inhibitorpharmacovigilanceskin of colorvitiligo

Identifiers

PMID42005505

DOI10.1016/j.jdcr.2026.02.038

PMCPMC13089052

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.